Utility of Procalcitonin (PCT) and Mid regional pro-Adrenomedullin (MR-proADM) in risk stratification of critically ill febrile patients in Emergency Department (ED). A comparison with APACHE II score

Overview of attention for article published in BMC Infectious Diseases, August 2012

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (86th percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

twitter: 2 X users

patent: 4 patents

Readers on

mendeley: 86 Mendeley

Summary X Patents

So far, Altmetric has seen 4 patents that reference this research output.

PROADM AS MARKER INDICATING AN ADVERSE EVENT

Application EP-4220175-A1

European Patent Office

PRO-ADM as a therapeutic monitoring marker for critically ill patients

Application JP-2020533604-A

Japan

WORKFLOW FOR RISK ASSESSMENT AND PATIENT MANAGEMENT USING PROCALCITONIN AND MIDREGIONAL-PRO…

Application WO-2019122100-A1

World Intellectual Property Organisation (WIPO)

PROADM AS MARKER INDICATING AN ADVERSE EVENT

Application WO-2018141840-A1

World Intellectual Property Organisation (WIPO)

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.